Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.

Détails

ID Serval
serval:BIB_0D07AF028847
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.
Périodique
European Heart Journal
Auteur(s)
Brakch N., Dormond O., Bekri S., Golshayan D., Correvon M., Mazzolai L., Steinmann B., Barbey F.
ISSN
1522-9645[electronic], 0195-668X[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
31
Numéro
1
Pages
67-76
Langue
anglais
Résumé
AIMS: A hallmark of Fabry disease is the concomitant development of left-ventricular hypertrophy and arterial intima-media thickening, the pathogenesis of which is thought to be related to the presence of a plasmatic circulating growth-promoting factor. We therefore characterized the plasma of patients with Fabry disease in order to identify this factor. METHODS AND RESULTS: Using a classical biochemical strategy, we isolated and identified sphingosine-1 phosphate (S1P) as a proliferative factor present in the plasma of patients with Fabry disease. Plasma S1P levels were significantly higher in 17 patients with Fabry disease compared with 17 healthy controls (225 +/- 40 vs. 164 +/- 17 ng/mL; P = 0.005). There was a positive correlation between plasma S1P levels and both common carotid artery intima-media thickness and left-ventricular mass index (r(2) = 0.47; P = 0.006 and r(2) = 0.53; P = 0.0007, respectively). In an experimental model, mice treated with S1P developed cardiovascular remodelling similar to that observed in patients with Fabry disease. CONCLUSION: Sphingosine-1 phosphate participates in cardiovascular remodelling in Fabry disease. Our findings have implications for the treatment of cardiovascular involvement in Fabry disease.
Pubmed
Web of science
Création de la notice
28/09/2009 14:35
Dernière modification de la notice
03/03/2018 13:39
Données d'usage